Huge Gap Between Drug Prices to Retailers and Maximum Retail Prices

📌 GS Paper Mapping for UPSC
  • GS Paper 2: Health, government policies, regulatory institutions, welfare.
  • GS Paper 3: Pharmaceutical industry, regulation, market mechanisms.
  • Essay: Universal healthcare, affordability of healthcare, regulatory governance

Why in News?

During recent proceedings, the SC highlighted an example where a cancer medicine supplied to a retailer at around ₹2,700 carried an MRP of ₹27,000, raising questions over the adequacy of India’s existing drug-price regulation framework.

What is PTR and MRP?

Price to Retailer (PTR): The price at which a manufacturer/distributor supplies a medicine to a retailer.
Maximum Retail Price (MRP): The maximum price at which the medicine can legally be sold to the consumer, subject to applicable taxes and regulatory provisions.

Drug Price Regulation in India:

Drug pricing in India is primarily governed by the Drugs (Prices Control) Order, 2013 (DPCO), issued under the Essential Commodities Act, 1955.

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, regulates prices of medicines covered by the DPCO.

Scheduled medicines: For medicines included in Schedule I of the DPCO, generally corresponding to medicines in the National List of Essential Medicines (NLEM), NPPA determines a ceiling price.

The ceiling price is calculated using the market-based pricing methodology, with a 16% retailer margin added to the average price to retailer.

Thus:

Average PTR + 16% retailer margin = Ceiling Price

Applicable taxes are added subsequently to arrive at the MRP.

The Regulatory Gap:

A major issue is the distinction between scheduled and non-scheduled medicines.

  • For scheduled medicines, prices are subject to the ceiling-price mechanism.
  • For non-scheduled medicines, manufacturers have considerably greater pricing freedom, although the DPCO restricts annual increases in MRP to 10% over the preceding 12 months.

Key Challenges in Drug Price Regulation:

  1. Affordability vs pharmaceutical innovation: Excessively stringent price controls could affect incentives for research, manufacturing and introduction of new medicines.
  2. Scheduled vs non-scheduled medicines: The differential regulatory treatment creates questions regarding whether price regulation should depend primarily on a medicine’s classification or its therapeutic importance.
  3. Complex supply chains: Manufacturer → distributor → wholesaler → retailer/hospital pharmacy can involve multiple margins, making effective monitoring difficult.
  4. Hospital-specific procurement: Hospitals may negotiate procurement prices that are substantially below the printed MRP, creating questions regarding how the resulting margins are distributed.
  5. Information asymmetry: Patients often lack access to sufficient information about procurement prices and comparable alternatives.

Way Forward:

  • Strengthen price transparency by improving public access to PTR and MRP information.
  • Improve NPPA monitoring of unusual price differentials.
  • Examine whether trade-margin regulation can complement ceiling-price regulation for selected categories of medicines.
  • Strengthen enforcement against overcharging.
  • Promote generic prescribing and generic substitution, while ensuring quality and availability.
  • Examine hospital pharmacy practices from the perspective of consumer choice and competition.
  • Maintain a balance between affordable medicines and incentives for pharmaceutical innovation.
  • Periodically review the distinction between scheduled and non-scheduled medicines, especially for life-saving therapies.

Mains Practice Question:

Q. The wide gap between the Price to Retailer (PTR) and Maximum Retail Price (MRP) of medicines raises concerns regarding the affordability and regulation of healthcare in India. Discuss the underlying regulatory challenges and suggest measures to ensure reasonable drug pricing without discouraging pharmaceutical innovation. (15 marks, 250 words)